
Altria Group and Philip Morris International have ended merger discussions with Altria over e-cigarettes, reported The Wall Street Journal.
“While we believed the creation of a new merged company had the potential to create incremental revenue and cost synergies, we could not reach an agreement,” said Howard Willard, Altria’s CEO. “We look forward to continuing our commercialization of IQOS in the US under our existing arrangements.”
The two sides had been negotiating for weeks, but the Philip Morris board became increasingly uncomfortable with the deal amid the shifting US regulatory environment, said one person familiar with the matter.
Tobacco stocks have slumped after reports emerged the Food and Drug Administration announced it’s investigating 127 reports of seizures after vaping. Altria owns Juul Labs, which has come under fire for marketing unauthorized, modified risk tobacco products, including to youth.
The FDA has received around 92 new reports of people, especially kids and young adults, experiencing seizures after using e-cigarettes since it first announced its probe into the issue in April. It is unclear whether the e-cigarettes caused the seizures, reported the WSJ.
Full Content: Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas